Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Key Takeaways TRIUMPH-4 Phase 3 results (December 2025): 28.7% average body weight loss at 68 weeks on the 12mg dose vs 2.1% on placebo TRIUMPH program scope: Over 5,800 participants across four core trials covering obesity, type 2 diabetes, cardiovascular outcomes, and knee osteoarthritis Additional trials enrolling (April 2026): TRIUMPH-7, -8, and -9 are actively recruiting at Lilly trial sites How to enroll: Search ClinicalTrials.gov for retatrutide or call Lilly at 1-877-CTLILLY Retatrutide is investigational: Not FDA-approved as of April 2026
Rapid repair of injured gastric mucosa
Nutrients, 15 (1), 160
Proper injection technique, site rotation, and allowing medication to reach room temperature can further minimize discomfort
How will the BALANCE Model affect my plan choices for 2027
Many people taking Ozempic (a semaglutide) have suffered from severe gastrointestinal complications that they say they were not properly warned about
US$ 26.71
US$ 22.42
US$ 22.06
US$ 22.65
US$ 29.06
US$ 20.65
US$ 26.95
US$ 27.76
US$ 28.27
US$ 21.62
US$ 20.78
US$ 27.23
